<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04475536</url>
  </required_header>
  <id_info>
    <org_study_id>EPIC08-TANSEI</org_study_id>
    <nct_id>NCT04475536</nct_id>
  </id_info>
  <brief_title>A Prospective Study, Single-arm, Multicentre, Observational to Evaluate Safety and Effectiveness of Stent Ultimaster Tansei Coronary Stent in Complex Coronary Lesions.</brief_title>
  <acronym>TANSEI</acronym>
  <official_title>A Prospective Study, Single-arm, Multicentre, Observational to Evaluate Safety and Effectiveness of Stent Ultimaster Tansei Coronary Stent in Complex Coronary Lesions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación EPIC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación EPIC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective registry is intended to evaluate the safety and efficacy of the TANSEI
      stent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective registry is intended to analyze clinical outcomes in patients treated with
      TANSEI stent in patients with complex coronary lesions .
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Safety.The composite of cardiac death, myocardial infarction (MI) and stent thrombosis (Academic Research Consortium definitive/probable).</measure>
    <time_frame>12 months</time_frame>
    <description>The composite of cardiac death, myocardial infarction (MI) and stent thrombosis (Academic Research Consortium definitive/probable).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy.The incidence of clinically driven target lesion revascularization.</measure>
    <time_frame>12 months</time_frame>
    <description>The incidence of clinically driven target lesion revascularization (TLR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All death.</measure>
    <time_frame>12 months</time_frame>
    <description>All death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death.</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel revascularization.</measure>
    <time_frame>12 months</time_frame>
    <description>Target Vessel revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization.</measure>
    <time_frame>12 months</time_frame>
    <description>Target lesion revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (ARC definite/probable).</measure>
    <time_frame>12 months</time_frame>
    <description>Stent thrombosis (ARC definite/probable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding event (BARC type 2-5).</measure>
    <time_frame>12 months</time_frame>
    <description>Major bleeding event (BARC type 2-5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke.</measure>
    <time_frame>12 months</time_frame>
    <description>Stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success.</measure>
    <time_frame>12 months</time_frame>
    <description>Procedural success ( Residual stenosis &lt;30% after implantation at the narrowest point of the treated vascular segment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with DAPT</measure>
    <time_frame>From 1 to 6 months</time_frame>
    <description>Rate of patients with DAPT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with DAPT</measure>
    <time_frame>From 6 to 12 months</time_frame>
    <description>Rate of patients with DAPT</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Coronary Artery Disease (CAD)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TANSEI stent</intervention_name>
    <description>stenting with the TANSEI sirolimus-eluting stent</description>
    <arm_group_label>Coronary Artery Disease (CAD)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with de novo native and complex coronary artery lesions, candidate to undergo
        revascularisation with a coronary device.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt; 18 years.

          -  With indication of percutaneous revascularization.

          -  Complex coronary lesion defined as:

               -  Left main lesion AND/OR

               -  Lesion located at a major bifurcation (side branch &gt;2mm) AND/OR

               -  Lesion located in a small vessel (&lt;2.5 mm reference diameter by visual
                  estimation) AND/OR

               -  Lesion length &gt; 35 mm

          -  Informed consent signed.

        Exclusion Criteria:

          -  Cardiogenic shock at the time of the PCI(Percutaneous Coronary Intervention).

          -  Life expectancy of the patient under 1 year.

          -  Patients included in other studies or clinical trials.

          -  Clinical decision that excludes the use of drug-eluting stents.

          -  Confirmed allergy to aspirin and / or thienopyridines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bruno Garcia del Blanco, MD, PhD</last_name>
    <phone>+34932746155</phone>
    <email>brunogb51@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fundacion Epic</last_name>
    <phone>+34987876135</phone>
    <email>iepic@fundacionepic.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario de León</name>
      <address>
        <city>León</city>
        <zip>24001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Saito S, Valdes-Chavarri M, Richardt G, Moreno R, Iniguez Romo A, Barbato E, Carrie D, Ando K, Merkely B, Kornowski R, Eltchaninoff H, James S, Wijns W; CENTURY II Investigators. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. Eur Heart J. 2014 Aug 7;35(30):2021-31. doi: 10.1093/eurheartj/ehu210. Epub 2014 May 19.</citation>
    <PMID>24847155</PMID>
  </reference>
  <reference>
    <citation>Orvin K, Carrie D, Richardt G, Desmet W, Assali A, Werner G, Ikari Y, Fujii K, Goicolea J, Dangoisse V, Manari A, Saito S, Wijns W, Kornowski R. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial. Catheter Cardiovasc Interv. 2016 May;87(6):1092-100. doi: 10.1002/ccd.26150. Epub 2015 Aug 13.</citation>
    <PMID>26268482</PMID>
  </reference>
  <reference>
    <citation>Lesiak M, Araszkiewicz A, Grajek S, Colombo A, Lalmand J, Carstensen S, Namiki A, Tobaru T, Merkely B, Moreno R, Barbato E, Wijns W, Saito S. Long Coronary Lesions Treated With Thin Strut Bioresorbable Polymer Drug Eluting Stent: Experience From Multicentre Randomized CENTURY II Study. J Interv Cardiol. 2016 Feb;29(1):47-56. doi: 10.1111/joic.12262.</citation>
    <PMID>26864951</PMID>
  </reference>
  <reference>
    <citation>Derimay F, Souteyrand G, Motreff P, Rioufol G, Finet G. Influence of platform design of six different drug-eluting stents in provisional coronary bifurcation stenting by rePOT sequence: a comparative bench analysis. EuroIntervention. 2017 Oct 13;13(9):e1092-e1095. doi: 10.4244/EIJ-D-16-00863.</citation>
    <PMID>28485275</PMID>
  </reference>
  <reference>
    <citation>Chevalier B, Smits PC, Carrié D, Mehilli J, Van Boven AJ, Regar E, Sawaya FJ, Chamié D, Kraaijeveld AO, Hovasse T, Vlachojannis GJ. Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging: The DISCOVERY 1TO3 Study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months). Circ Cardiovasc Interv. 2017 Dec;10(12). pii: e004801. doi: 10.1161/CIRCINTERVENTIONS.116.004801.</citation>
    <PMID>29246909</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Complex Lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

